B lymphocytes - The physiological role and implication in the pathogenesis of rheumatoid arthritis;Limfocyty B - Funkcje fizjologiczne i udział w patogenezie reumatoidalnego zapalenia stawów

Reumatologia

Volumn 44, Issue 3, 2006, Pages 150-161

  Kontny, Ewa ^a   Maśliński, Włodzimierz ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

B lymphocytes; Immunopathogenesis; Rheumatoid arthritis

Indexed keywords

AUTOANTIGEN; CYTOKINE; GROWTH FACTOR;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL CLONING; CELL CONTACT; CELL MATURATION; CYTOKINE PRODUCTION; DNA POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; INFLAMMATION; LYMPHATIC SYSTEM; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 33745940947     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Budd RC, Fortner KA. T lymphocytes. In: Kelley's Textbook of Rheumatology. Harris ED Jr, Budd RC, Firestein GS, et al. (eds). Elsevier Saunders, Philadelphia 2005; 133-54.
2. Diamond B, Grimaldi C. B cells. In: Kelley's Textbook of Rheumatology. Harris ED Jr, Budd RC, Firestein GS, et al. (eds). Elsevier Saunders, Philadelphia 2005; 153-73.
3. Grimaldi MCh, Hicks R, Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol 2005; 174: 1775-81.
4. Hillion S, Rochas C, Youinou P, et al. Expression and reexpression of recombination activating genes. Relevance to the development of autoimmune states. Ann N Y Acad Sci 2005; 1050: 10-8.
5. Manis JP, Tian M, Alt FW. Mechanism and control of class-switch recombination. Trends Immunol 2002; 23: 31-9.
6. Busslinger M. Transcriptional control of early B cell development. Ann Rev Immunol 2004; 22: 55-79.
7. Youinou P, Jamin Ch, Pers JO, et al. B lymphocytes are required for development and treatment of autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 19-33.
8. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 2004; 20: 517-27.
9. Howard LM, Miller SD. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease. Autoimmunity 2004; 37: 411-8.
10. Milner ECB, Anolik J, Cappione AA, et al. Human innate B cells: a link between host defense and autoimmunity? Springer Semin Immunopathol 2005; 26: 433-52.
11. Mitschke L, Tsubata T. Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends Immunol 2004; 25: 543-50.
12. Fujimoto M, Kuwano Y, Watanabe R, et al. B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation. J Immunol 2006; 176: 873-9.
13. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003; 5 (Suppl. 4): S1-S6.
14. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology 2005; 44 (Suppl. 2): ii3-ii7.
15. Kotzin BL. The role of B cells in the pathogenesis of rheumatoid arthritis. J Rheumatol 2005; 32 (Suppl. 73): 14-8.
16. Bayry J, Lacroix-Desmanez S, Kazatchkine MD, et al. Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol 2005; 175: 15-20.
17. Husson H, Lugli SM, Ghia P, et al. Functional effects of TNF and lymphotoxin alphalbeta2 on FDC-like cells. Cell Immunol 2000; 203: 134-43.
18. Shlomchik M, Mascelli M, Shan H, et al. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J Exp Med 1990; 171: 265-97.
19. Samuels J, Ng YS, Coupillaud C, et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2006; 201: 1659-67.
20. Samuels J, Ng YS, Coupillaud C, et al. Human B cell tolerance and its failure in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1062: 116-26.
21. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley's Textbook of Rheumatology. Harris ED Jr, Budd RC, Firestein GS, et al. (eds). Elsevier Saunders, Philadelphia 2005; 996-1042.
22. Tighe H, Carson DA. Rheumatoid factor. In: Kelley's Textbook of Rheumatology. Harris ED Jr, Budd RC, Firestein GS, et al. (eds). Elsevier Saunders, Philadelphia 2005; 301-10.
23. Nydegger UE. Immune complexes. In: Kelley's Textbook of Rheumatology. Harris ED Jr, Budd RC, Firestein GS, et al. (eds). Elsevier Saunders, Philadelphia 2005; 332-41.
24. Solomon S, Kassahn B, Illges H. The role of the complement and the FcγR system in the pathogenesis of arthritis. Arthritis Res Ther 2005; 7: 129-35.
25. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999; 97: 188-96.
26. Edwards JC, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology 2005; 44: 151-6.
27. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic cytrulinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. A prospective cohort study. Arthritis Rheum 2004; 50: 709-15.
28. Vossenaar ER, Zendman AJW, van Venrooij WJ. Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther 2004; 6: 1-5.
29. Utz PJ, Genovese MC, Robinson WH. Unlocking the "PAD" lock on rheumatoid arthritis. Ann Rheum Dis 2004; 63: 330-2.
30. Maccioni M, Zender-Lutz G, Huang H, et al. Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med 2002; 195: 1071-7.
31. Mastumoto I, Maccionni M, Lee DM, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 2002; 3: 360-5.
32. Hirano T. Revival of the autoantibody model in rheumatoid arthritis. Nat Immunol 2002; 3: 342-4.
33. Kamradt T, Schubert D. The role and clinical implications of G6PI in experimental models of rheumatoid arthritis. Arthritis Res Ther 2004; 7: 20-8.
34. Weyand CM, Seyler T, Goronzy JJ. B cells in rheumatoid synovitis. Arthritis Res Ther 2005; 7 (Suppl. 3): S9-S12.
35. Tsubaki T, Takegawa S, Hanamoto H, et al. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol 2005; 141: 363-71.
36. Manzo A, Paoletti S, Carulli M, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005; 35: 1347-59.
37. Cupedo T, Mebius RE. Cellular interactions in lymph node development. J Immunol 2005; 174: 21-5.
38. Yazdany J, Davis J. The role of CD40 ligand in systemic erythematosus. Lupus 2004; 13: 377-80.
39. Cron RQ. A signal achievment in the treatment of arthritis. Arthritis Rheum 2005; 52: 2229-32.
40. Dall'Era M, Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus 2004; 13: 372-6.
41. Carlton VE, Hu X, Chokkalingam AP, et al. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am J Hum Genet 2005; 77: 567-81.
42. Johansson M, Ärlestig L, Hallmans G, et al. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther 2005; 8: R19.
43. Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174: 864-70.
44. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2: 465-75.
45. Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 153: 807-17.
46. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34-9.
47. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 655-6.
48. Seyler TM, Park YW, Takemura S, et al. BlyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115: 3083-92.
49. Ramanujam M, Davidson A. The current status of targeting BAFF/BlyS for autoimmune diseases. Arthritis Res Ther 2004; 6: 197-202.
50. Keystone E. B cell targeted therapies. Arthritis Res Ther 2005; 7 (Suppl. 3): S13-S18.
51. Goldblatt F, Isenberg DA New therapies for rheumatoid arthritis. Clin Exp Immunol 2005; 140: 195-204.
52. He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004; 173: 4479-91.
53. Kontny E, Rudnicka W, Maśliński W. Receptory Toll-podobne: znaczenie fizjologiczne i udział w patogenezie chorób reumatycznych. Reumatologia 2004; 42: 551-66.
54. Rifkin IR, Ledbetter EA, Busconi L, et al. Toll-like receptors, endogenous ligands, and systemic autoimmune diseases, Immunol Rev 2005; 204: 27-42.
55. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202: 1171-7.
56. Varambally S, Bar-Dayan Y, Bayry J, et al. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol 2004; 16: 517-24.
57. Shoenfeld Y, Toubi E. Protective autoantibodies. Role in homeostasis, clinical impotance, and therapeutic potential. Arthritis Rheum 2005; 52: 2599-606.
58. Wildbaum G, Nahir MA, Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 2003; 19: 679-88.
59. Sherer Y, Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 2006; 5: 153-5.
60. Mockridge CI, Rahman A, Buchan S, et al. Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity 2004; 37: 9-15.